Providing details on any new indications not only informs the market, but it also informs potential competitors who may be considering product development for those indications.
The later others know of Neuren’s intentions the better.
Silence should allow NEU to have the advantage of first into relevant Phase 2 trials.
- Forums
- ASX - By Stock
- Ann: Trofinetide marketing application submitted in Europe
NEU
neuren pharmaceuticals limited
Add to My Watchlist
6.14%
!
$13.31

Providing details on any new indications not only informs the...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.31 |
Change
0.770(6.14%) |
Mkt cap ! $1.655B |
Open | High | Low | Value | Volume |
$12.96 | $14.00 | $12.91 | $19.76M | 1.453M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3000 | $13.30 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.33 | 3716 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3000 | 13.300 |
2 | 10200 | 13.200 |
1 | 2500 | 13.190 |
2 | 1750 | 13.180 |
1 | 50 | 13.170 |
Price($) | Vol. | No. |
---|---|---|
13.330 | 3716 | 1 |
13.370 | 3716 | 1 |
13.390 | 600 | 1 |
13.400 | 3783 | 2 |
13.430 | 3716 | 1 |
Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online